AMNEAL PHARMACEUTICALS (AMRX) Competitors $10.41 +0.03 (+0.30%) As of 02:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMRX vs. ASND, VTRS, ROIV, QGEN, BBIO, MRNA, ELAN, VRNA, RVMD, and GRFSShould you be buying AMNEAL PHARMACEUTICALS stock or one of its competitors? The main competitors of AMNEAL PHARMACEUTICALS include Ascendis Pharma A/S (ASND), Viatris (VTRS), Roivant Sciences (ROIV), QIAGEN (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry. AMNEAL PHARMACEUTICALS vs. Its Competitors Ascendis Pharma A/S Viatris Roivant Sciences QIAGEN BridgeBio Pharma Moderna Elanco Animal Health Verona Pharma PLC American Depositary Share Revolution Medicines Grifols AMNEAL PHARMACEUTICALS (NASDAQ:AMRX) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk. Do analysts prefer AMRX or ASND? AMNEAL PHARMACEUTICALS currently has a consensus target price of $12.00, suggesting a potential upside of 15.22%. Ascendis Pharma A/S has a consensus target price of $244.36, suggesting a potential upside of 21.23%. Given Ascendis Pharma A/S's higher possible upside, analysts plainly believe Ascendis Pharma A/S is more favorable than AMNEAL PHARMACEUTICALS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AMNEAL PHARMACEUTICALS 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Ascendis Pharma A/S 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, AMRX or ASND? AMNEAL PHARMACEUTICALS has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Which has better earnings & valuation, AMRX or ASND? AMNEAL PHARMACEUTICALS has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than AMNEAL PHARMACEUTICALS, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAMNEAL PHARMACEUTICALS$2.79B1.17-$116.89M$0.011,041.50Ascendis Pharma A/S$393.54M31.56-$409.12M-$5.16-39.06 Does the media prefer AMRX or ASND? In the previous week, AMNEAL PHARMACEUTICALS had 4 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 6 mentions for AMNEAL PHARMACEUTICALS and 2 mentions for Ascendis Pharma A/S. AMNEAL PHARMACEUTICALS's average media sentiment score of 0.93 beat Ascendis Pharma A/S's score of 0.57 indicating that AMNEAL PHARMACEUTICALS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AMNEAL PHARMACEUTICALS 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is AMRX or ASND more profitable? AMNEAL PHARMACEUTICALS has a net margin of 0.12% compared to Ascendis Pharma A/S's net margin of -54.94%. Ascendis Pharma A/S's return on equity of 0.00% beat AMNEAL PHARMACEUTICALS's return on equity.Company Net Margins Return on Equity Return on Assets AMNEAL PHARMACEUTICALS0.12% -189.49% 6.17% Ascendis Pharma A/S -54.94%N/A -24.31% Do insiders and institutionals have more ownership in AMRX or ASND? 31.8% of AMNEAL PHARMACEUTICALS shares are held by institutional investors. 26.6% of AMNEAL PHARMACEUTICALS shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryAMNEAL PHARMACEUTICALS beats Ascendis Pharma A/S on 10 of the 15 factors compared between the two stocks. Get AMNEAL PHARMACEUTICALS News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMRX vs. The Competition Export to ExcelMetricAMNEAL PHARMACEUTICALSMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.26B$2.59B$6.03B$10.56BDividend YieldN/A60.73%5.92%4.70%P/E Ratio1,040.5424.3376.4426.46Price / Sales1.17721.82582.24128.91Price / Cash7.21180.3238.1961.33Price / Book-29.765.2612.516.45Net Income-$116.89M$32.92M$3.30B$277.12M7 Day Performance8.49%3.58%28,070.97%1.50%1 Month Performance8.72%8.87%30,461.56%7.93%1 Year Performance21.25%-4.69%35,708.14%36.01% AMNEAL PHARMACEUTICALS Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMRXAMNEAL PHARMACEUTICALS3.0198 of 5 stars$10.41+0.3%$12.00+15.3%+19.3%$3.27B$2.79B1,042.548,100ASNDAscendis Pharma A/S3.5728 of 5 stars$196.42-0.6%$244.36+24.4%+39.2%$12.18B$393.54M-38.071,017High Trading VolumeVTRSViatris1.4514 of 5 stars$9.79-1.1%$10.40+6.2%-12.2%$11.54B$14.74B-3.3832,000ROIVRoivant Sciences3.816 of 5 stars$14.94-0.7%$19.94+33.5%+38.5%$10.27B$29.05M-21.34860QGENQIAGEN4.5207 of 5 stars$45.72-0.5%$49.69+8.7%+5.9%$10.21B$1.98B27.015,765Analyst ForecastBBIOBridgeBio Pharma4.4593 of 5 stars$51.54-1.6%$63.94+24.1%+115.6%$10.01B$221.90M-12.60400MRNAModerna4.3394 of 5 stars$26.56+5.2%$41.81+57.4%-56.8%$9.82B$3.24B-3.535,800Trending NewsOptions VolumeELANElanco Animal Health2.6637 of 5 stars$19.08-0.6%$17.33-9.2%+43.4%$9.54B$4.44B22.199,000News CoverageVRNAVerona Pharma PLC American Depositary Share1.8514 of 5 stars$106.25+0.2%$109.00+2.6%+268.5%$9.14B$42.28M-107.3230Positive NewsRVMDRevolution Medicines4.2335 of 5 stars$44.41+2.0%$73.67+65.9%+1.5%$8.14B$11.58M-9.87250GRFSGrifols3.3491 of 5 stars$9.70-0.4%$10.30+6.2%+12.9%$6.70B$7.81B8.2923,822Short Interest ↑ Related Companies and Tools Related Companies ASND Competitors VTRS Competitors ROIV Competitors QGEN Competitors BBIO Competitors MRNA Competitors ELAN Competitors VRNA Competitors RVMD Competitors GRFS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMRX) was last updated on 10/2/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredThis Biotech has a clinical approach that intrigues investorsThis biotech is gearing up for Phase 2 trials with a strategy to unlock multiple approvals from one study. ...i2i Marketing Group, LLC | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AMNEAL PHARMACEUTICALS, INC. Please log in to your account or sign up in order to add this asset to your watchlist. Share AMNEAL PHARMACEUTICALS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
